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Association guidelines give aspirin a class I indication for use in
patients with chronic stable angina (level of evidence A) (3). This
recommendation, however, has been interpreted to embrace a
myriad of aspirin formulations: various salts, polymer-coated in
rapid-release (compressed, soluble), buffered, and enteric-coated
preparations, which may influence the bioavailability of the prep-
aration (4). We recently evaluated the effect of low-dose enteric-
coated aspirin preparations on platelet COX-1 in both healthy
volunteers and patients with stable CAD. Low-dose enteric-coated
aspirin failed to inhibit platelet cyclooxygenase in some individuals.
Specifically younger, heavier patients and those with a history of
prior myocardial infarction were less likely to have an adequate
response (5).
Not withstanding the initial uncontrolled studies, we agree that
the jury is still out on the clinical relevance of aspirin resistance.
However, it is not an unreasonable goal that a drug has its intended
pharmacological effect. In the case of aspirin, near complete
inhibition of platelet cyclooxygenase is most likely to be achieved
with the correct preparation and dose.
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REPLY
We appreciate the comments and criticisms voiced by Dr. Maree
and colleagues. With respect to pharmacodynamic heterogeneity
and genotypic variation in cyclooxygenase (COX)-1, we applaud
the investigators’ work and agree that the single haplotype iden-
tified may contribute to, but not entirely explain, the phenomenon
of “aspirin resistance.” As suggested in our study (1), variation in
aspirin responsiveness is most likely explained by a combination of
several processes. If true, however, that 12% of the investigators’
cohort with stable coronary artery disease carried the specific
COX-1 haplotype, it may prove interesting to study this popula-
tion in greater detail. We also find interesting the observation by
Dr. Maree et al. that low-dose (75 mg) enteric-coated aspirin
failed to inhibit platelet COX in certain individuals. Although
previously studied in some detail, the effects of aspirin dose and
formulation are still worthy of further investigation. Finally, we
agree that the biological validity and clinical relevance of “aspirin
resistance” remains somewhat unproven.
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The Emperor’s New
Clothes Are Loose: Lower Body
Mass Index, Not Calorie Restriction,
Accounts for Improved Diastolic Function
A recent study in JACC (1) concludes that diastolic function is
improved in individuals on long-term calorie restriction (CR)
compared to those eating a “Western diet.” We would like to point
out that other studies demonstrate a correlation between diastolic
dysfunction and body mass index (BMI) as an independent factor.
In the study by Fontana et al. (1), control subjects eating a Western
diet had an average BMI of 27 kg/m2; the CR adherents had a
BMI of 19.7 kg/m2. Mortality and morbidity rise significantly
above a BMI of 22 kg/m2, and a BMI of 25 kg/m2 is (generously)
considered by U.S. Department of Agriculture panelists as the
upper limit of normal weight. Therefore, a BMI of 27 kg/m2 is
well within the category of overweight. An average male height 5
ft 9 inches with a BMI of 20 kg/m2 weighs 135 lbs. If his BMI is
27 kg/m2, he weighs 35% more at 182 lbs, a 47-lb difference!
In a study of the effect of isolated obesity on diastolic function
Pascual et al. (2), state: “Subclinical left ventricular diastolic
dysfunction is present in all grades of isolated obesity, correlates
with BMI, and is associated with increased systolic function in the
early stages of obesity.” In that study, a BMI between 25 and 29.9
kg/m2 was classed as “slight obesity.” Another study (3) states:
“Diastolic function was negatively correlated with age, BMI,
systolic blood pressure, diastolic blood pressure and left ventricular
mass index.”
In addition, control subjects had 26% body fat, and the CR
subjects had 9.3%. Obesity is known to raise tumor necrosis
factor-alpha and other pro-inflammatory cytokines (4). Long-term
inflammatory effects may change ventricular elasticity, but the
observed difference may be due more to the large difference in body
fat and BMI than to the CR versus Western diets. It is probable
that the difference in diastolic function attributed to CR is at least
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partly due to the secondary effect of being thin, and not the direct
result of the CR diet.
Finally, the small number of adherents to a CR life-style speaks
to the difficulty in depriving oneself every day of preferred type and
amounts of food. We hypothesize (5) that alternate-day calorie
restriction, in which one eats less and more than needed to maintain
body weight on alternating days, will provide the same health benefits
as daily CR; it is a much more agreeable way of living, and it appears
to have a profound effect on cardiac function (6).
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REPLY
We appreciate the views expressed by Dr. Johnson and colleagues
regarding our recent study (1) concerning caloric restriction (CR)
and diastolic function (DF). We agree that in large population
studies, diastolic dysfunction, body mass index (BMI), and adi-
posity are correlated. It would be ideal to have a BMI and
body-fat–matched control group that is healthy and not calorie
restricted. However, it is self-evident that such a control group is
not readily available. It would be extremely difficult to find healthy
individuals, other than extreme endurance athletes, who have a
BMI 20 kg/m2 who are not calorie restricted. Individuals with a
BMI 20 kg/m2 who are not endurance athletes or calorie
restricted are generally in ill-health and frail or heavy smokers.
Endurance exercise training causes major cardiovascular adapta-
tions, so athletes are also not an appropriate control group. The
control group in our study consisted of individuals typical of the
U.S. population, as 78.2% of the men and 68.1% of the women
older than 40 years are overweight or obese in the U.S. (2).
In our study (1) we provided evidence that, in humans,
long-term CR with optimal nutrition (at least 100% of the
recommended daily intake for each nutrient) results in very low
levels of inflammation, as demonstrated by low serum C-reactive
protein and tumor necrosis factor-alpha concentration, and re-
duced left ventricular stiffness, indicated by the lower model-based
image processing–derived chamber stiffness parameter k and vis-
coelastic chamber constant c. We also found that CR is associated
with low serum concentrations of transforming growth factor-beta,
a powerful pro-fibrotic molecule that plays a role in regulating the
myocardial composition of the extracellular matrix, thus potentially
having salutary effects on k and c (3).
In contrast, individuals who are very thin owing to chronic
diseases generally have elevated levels of systemic inflammation
and have diastolic dysfunction despite a low BMI (4–6). For the
group considered, long-term CR is the cause, and the coexistent
low BMI is one effect. Conversely, we are not aware of any
mechanism by which a low BMI, as an independent variable, can
improve DF. The improved DF observed is mediated by other CR
effects, such as lowering blood pressure and decreasing the levels of
inflammatory cytokines, hormones, and growth factors that may
reduce fibrosis, increase compliance, and improve cardiac effi-
ciency.
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Implications and Controversies
of Recent Hypertension Trials
Williams has written a comprehensive and thought-provoking
review of the recent hypertension literature (1). One of his major
contentions is an iteration of the hypothesis that achieving better
cardiovascular outcomes depends on more aggressive blood pres-
sure (BP) control and not on the specific choice of antihypertensive
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